EXECUTIVE SUMMARY - GOLD

86. Ackermann-Liebrich U, Leuenberger P,
Schwartz J, Schindler C, Monn C, Bolognini
G, et al. Lung function and long term
exposure to air pollutants in Switzerland.
Study on Air Pollution and Lung Diseases in
Adults (SAPALDIA) Team. Am J Respir Crit
Care Med 1997;155(1):122-9.
87. Reis AL. Response to bronchodilators. In:
Clausen J, ed. Pulmonary function testing:
guidelines and controversies. New York:
Academic Press; 1982.
88. Janelli LM, Scherer YK, Schmieder LE. Can
a pulmonary health teaching program alter
patients’ ability to cope with COPD? Rehabil
Nurs 1991;16(4):199-202.
89. Ashikaga T, Vacek PM, Lewis SO.
Evaluation of a community-based education
program for individuals with chronic
obstructive pulmonary disease. J Rehabil
1980;46(2):23-7.
90. Toshima MT, Kaplan RM, Ries AL.
Experimental evaluation of rehabilitation in
chronic obstructive pulmonary disease: shortterm
effects on exercise endurance and health
status. Health Psychol 1990;9(3):237-52.
91. Celli BR. Pulmonary rehabilitation in patients
with COPD. Am J Respir Crit Care Med
1995;152(3):861-4.
92. Stewart MA. Effective physician-patient
communication and health outcomes: a
review. CMAJ 1995;152(9):1423-33.
93. Clark NM, Nothwehr F, Gong M, Evans D,
Maiman LA, Hurwitz ME, et al. Physicianpatient
partnership in managing chronic
illness. Acad Med 1995;70(11):957-9.
94. Heffner JE, Fahy B, Hilling L, Barbieri C.
Outcomes of advance directive education of
pulmonary rehabilitation patients. Am J
Respir Crit Care Med 1997;155(3):1055-9.
95. Pauwels RA, Lofdahl CG, Laitinen LA,
Schouten JP, Postma DS, Pride NB, et al.
Long-term treatment with inhaled budesonide
in persons with mild chronic obstructive
pulmonary disease who continue smoking.
European Respiratory Society Study on
Chronic Obstructive Pulmonary Disease. N
Engl J Med 1999;340(25):1948-53.
96. Vestbo J, Sorensen T, Lange P, Brix A, Torre
P, Viskum K. Long-term effect of inhaled
budesonide in mild and moderate chronic
obstructive pulmonary disease: a randomised
controlled trial. Lancet 1999;353(9167):1819-
23.
97. Burge PS, Calverley PM, Jones PW, Spencer
S, Anderson JA, Maslen TK. Randomised,
double blind, placebo controlled study of
fluticasone propionate in patients with
moderate to severe chronic obstructive
pulmonary disease: the ISOLDE trial. BMJ
2000;320(7245):1297-303.
98. Vathenen AS, Britton JR, Ebden P, Cookson
JB, Wharrad HJ, Tattersfield AE. High-dose
inhaled albuterol in severe chronic airflow
limitation. Am Rev Respir Dis
1988;138(4):850-5.
99. Gross NJ, Petty TL, Friedman M, Skorodin
MS, Silvers GW, Donohue JF. Dose response
to ipratropium as a nebulized solution in
patients with chronic obstructive pulmonary
disease. A three-center study. Am Rev Respir
Dis 1989;139(5):1188-91.
100. Chrystyn H, Mulley BA, Peake MD. Dose
response relation to oral theophylline in